-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Candel Therapeutics Inc. (CADL)
-
-
-
-
-
-
-
LifeSci Capital Starts Candel Therapeutics Inc. (CADL) at Outperform
-
-
-
-
-
-
-
Candel receives EMA orphan designation for pancreatic cancer drug
-
-
-
-
-
-
-
Candel Therapeutics (CADL) Appoints Maha Radhakrishnan to its Board
-
-
-
-
-
-
-
Candel Therapeutics (CADL) Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409
-
-
-
-
-
-
-
Candel Therapeutics (CADL) Prices Public Offering
-
-
-
-
-
-
430,614 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

